Soen, Satoshi http://orcid.org/0000-0002-0955-2747
Uemura, Yukari
Tanaka, Shiro
Takeuchi, Yasuhiro
Endo, Naoto
Takada, Junichi
Ikeda, Satoshi
Iwamoto, Jun
Okimoto, Nobukazu
Tanaka, Sakae
Funding for this research was provided by:
Public Health Research Foundation
Asahi Kasei Pharma Corporation
Article History
Received: 17 April 2024
Accepted: 24 May 2024
First Online: 11 June 2024
Declarations
:
: S Soen has received consulting fees, speaking fees, and/or honoraria from Amgen Inc., Asahi Kasei Pharma Corp., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan Co., Ltd., Mochida Pharma Co., Ltd., Ono Pharmaceutical Co., Ltd., Teijin Pharma Ltd., and UCB Japan Co., Ltd. Shiro Tanaka has received lecture fees from the Research Institute of Healthcare Data Science. He has received consultation fees and outsourcing fees from Eli Lilly and Company, Welby, Daiichi Sankyo Co., Ltd., Janssen Pharmaceutical K.K., Satt, and the Public Health Research Foundation. He has received research grants from the Japan Agency for Medical Research and Development, the Japanese Ministry of Health, Labour and Welfare, the Japanese Ministry of Education, Science and Technology, and Novo Nordisk. He engaged in a research project of the Japan Agency for Medical Research and Development. Y Takeuchi has received consulting fees, speaking fees, and/or honoraria from Amgen Inc., Asahi Kasei Pharma Corp., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Mochida Pharma Co., Ltd., and Teijin Pharma Ltd., Taisho Pharmaceutical Holdings Co. Ltd., Towa Pharmaceutical Co. Ltd. J Takada has received consulting fees and speaking fees from Amgen Inc., Asahi Kasei Pharma Corp., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Taisho Pharmaceutical Co., Ltd., Teijin Pharma Ltd. S Ikeda has received consulting fees, speaking fees, and/or honoraria from Amgen Inc., Asahi Kasei Pharma Corp., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan Co., Ltd., Pfizer Inc., Hisamitsu Pharmaceutical Co., Inc., Mochida Pharma Co., Ltd., Teijin Pharma Ltd., Towa Pharmaceutical Co., Ltd., and UCB Japan Co., Ltd. J Iwamoto has received speaking fees from Asahi Kasei Pharma Corp., Eisai Co., Ltd., Taisho Pharmaceutical Holdings Co., Ltd., Teijin Pharma Ltd., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Kaken Pharmaceutical Co., Ltd., Amgen Inc., Astellas Pharma Inc., Towa Pharmaceutical Co., Ltd. N Okimoto has received payments for lectures, including speakers' bureau fees from Asahi Kasei Pharma Corp., Amgen Inc., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan, and Teijin Pharma Ltd. Sakae Tanaka has received lecture fees from Teijin Pharma Ltd., Asahi Kasei Pharma Corp., Amgen Inc., and Daiichi Sankyo Co., Ltd., and research grants from Teijin Pharma Ltd., Asahi Kasei Pharma Corp., Daiichi Sankyo Co., Ltd., and Chugai Pharmaceutical Co., Ltd. Y Uemura and N Endo have no conflicts of interest.